Ionis signs $60M upfront deal with Roche for two RNA programs for Alzheimer's and Huntington's

IONIS PHARMACEUTICALS INC

Ionis receives $60M upfront; Roche gains exclusive worldwide rights to develop and commercialize two undisclosed RNA-targeting medicines.
Ionis responsible for pre-clinical advancement; Roche leads clinical development, manufacturing, and commercialization.
Ionis eligible for development, regulatory, and commercial milestone payments plus tiered royalties.
Programs target Alzheimer's disease and Huntington's disease; expands 10-year partnership including tominersen for HD.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IONIS PHARMACEUTICALS INC entered into a collaboration with Roche (effective 2023-09-27).

Action: entry
Agreement: collaboration
Counterparty: Roche
Effective: 2023-09-27

Exact text from the filing

On September 27, 2023, Ionis Pharmaceuticals, Inc. issued a press release announcing it has entered into an agreement with Roche for two early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer’s disease and Huntington’s disease.

View on SEC.gov

302 material agreements filed in the last 30 days. Browse all material agreements →

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-045401

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.